Articles from CoreTissue BioEngineering Inc.

CoreTissue BioEngineering Inc. (“CTBE”), a medical device start-up (Headquarters: Yokohama City, Kanagawa Prefecture, CEO: Yoji Jokura, Ph.D.) announces that the safety evaluation in the safety cohort of its clinical trial for anterior cruciate ligament (ACL) reconstruction with the medical device "Tissue Regenerative Ligament" (development code: CT-ACL001) sponsored by the company has been completed, and the randomized controlled cohort to verify safety and efficacy has been initiated. This randomized controlled cohort will use the standard treatment of ACL reconstruction using the patient's own hamstring tendon as the control group and will be conducted at six facilities nationwide: Tokyo Women's Medical University Hospital (where Professor Dr. Ken Okazaki, the clinical trial coordinator, is affiliated), Hirosaki University Hospital, Hiroshima University Hospital, Hokkaido University Hospital, Juntendo University Hospital, and Kobe University Hospital (listed in alphabetical order).

CoreTissue BioEngineering Inc. (“CTBE”), a medical device start-up developing an artificial ligament derived from decellularized animal tissue, is the first company to be accepted by R Accelerator Program, a joint initiative backed by Mitsubishi Corporation (Americas) (“MCA”) and Fogarty Innovation. This program is currently focused on helping high-potential Japanese medtech companies commercialize their products in the U.S. Over the course of the six-month program, CTBE will work closely with leadership from MCA and Fogarty Innovation to craft a business development plan for the U.S. market including regulatory and reimbursement strategies.

CoreTissue BioEngineering Inc., a medical device company developing an artificial ligament derived from decellularized animal tissue, was accepted into Johnson & Johnson Innovation - JPOD @ Boston.